News | August 10, 2009

HCSC Expands Pharmacy Adherence Program for Cholesterol-Lowering Drugs

August 10, 2009 – Health Care Service Corp. (HCSC), which operates the Blue Cross and Blue Shield plans in Illinois, New Mexico, Oklahoma and Texas, is expanding a successful new cholesterol medication adherence program that provides physicians with greater insight into their patients’ medication use.

The pharmacy adherence program has proven to increase the use of cholesterol medication by 25 percent for those not following their doctor’s orders, the company said. As the country’s largest customer-owned health insurer with 12.4 million members, HCSC wants the program to serve as a model for the healthcare system.

“By not taking cholesterol medications, many people are subjecting themselves to serious cardiovascular complications that could otherwise be prevented,” says Fawwaz M. Shoukfeh, M.D., a physician in Texas who sees great benefit from the program. “This allows us to better communicate with our patients, improve their health, and ultimately help reduce the cost of their care.”

Originally designed with its pharmacy benefits manager, Prime Therapeutics, the program allows HCSC to analyze pharmaceutical data to identify members not refilling their prescribed cholesterol medications. The company then notifies the patients and their physicians, who also receive a customized patient report that includes lab results, drug quantities filled, dispensed dates and refill due dates. Members of Blue Cross and Blue Shield of Texas have used the program since last year.

“In addition to increasing statin medication use, the program also can save money for our customers and members,” said Kevin Slavik, senior pharmacy director at HCSC. “Through a pharmacy benefit step therapy plan, we are able to encourage the use of generic medications.”

HCSC plans to expand the program to its other Blues plans in Illinois, New Mexico, Oklahoma this month. The program also will soon target diabetes and other conditions.

For more information:

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Study Discovers Anticoagulant Drugs Are Being Prescribed Against Safety Advice
News | Antiplatelet and Anticoagulation Therapies| July 25, 2017
July 25, 2017 — A study by researchers at the University of Birmingham has shown that general practitioners (GPs) are
long-duration dual anti-platelet therapy (L-DAPT) compared to short-duration dual antiplatelet (S-DAPT) after DES stent implantation
News | Antiplatelet and Anticoagulation Therapies| July 12, 2017
June 12, 2017 — Researchers have evaluated the long-term efficacy and safety of long-duration dual anti-platelet ther
Sex-Specific Cardiovascular Drug Dosages Needed to Reduce Adverse Reactions in Women
News | Womens Healthcare| July 07, 2017
Sex-specific cardiovascular drug dosages are needed to reduce adverse reactions in women, according to a position paper...
Bayer Now Enrolling Patients for Global Pulmonary Arterial Hypertension Study
News | Hypertension| July 05, 2017
Bayer has enrolled the first patient in a global Phase IV study assessing the clinical effects of riociguat in patients...
FDA Grants Priority Review of Xarelto sNDA for 10 mg Dose
News | Antiplatelet and Anticoagulation Therapies| June 29, 2017
Janssen Research & Development LLC announced the U.S. Food and Drug Administration (FDA) accepted for Priority...
radial access, transradial access trial using anticoagulants
News | Radial Access| June 15, 2017
June 15, 2017 — In patients undergoing t...
Cost comparison between NOACs, novel oral anticoagulants
News | Antiplatelet and Anticoagulation Therapies| May 31, 2017
May 31, 2017 – The results from the first real-world, matched head-to-head study comparing all-cause healthcare costs
Data was positive from the Watchman Left Atrial Appendage Closure (LAAC) Device from the EWOLUTION registry
News | Atrial Fibrillation| May 30, 2017
May 30, 2017 — Data was positive for safety and efficacy rates of the Watchman Left Atrial Appendage Closure (LAAC) D
Overlay Init